Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrm LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, De Valk HW, Lis ACS, Parrot-Roulaud FM, Tan KS, Higgins I, and Garcon D (1997)
Research peptides do not fall under the same drug approval framework as traditional pharmaceuticals, meaning GHK-Cu products cannot make therapeutic claims and are sold for research purposes only
Limitations - retrospective study based on ICD-9 codes, the patient group was those discharged from the hospital, lack of information on important confounders (smoking, alcohol, SES), lack of information on treatments/disease activity drharrismd.com #doctor #health #wellness #heart #cancer #inflammation To view or add a comment, sign in Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications - timely article by Jasmin Hundal, M.D.,DipABLM, M.S., M.P.H
De ella no pueden extraerse conclusiones sobre la seguridad o la tolerabilidad en humanos